Basic Information
| LncRNA/CircRNA Name | AK001796 |
| Synonyms | MIR4435-2HG, AGD2, AK001796, LINC00978, MIR4435-1HG, MIR4435-2HG |
| Region | GRCh38_2:111036776-111523376 |
| Ensemble | ENSG00000172965 |
| Refseq | NR_015395 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Cisplatin | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot etc. |
| Sample | cell lines (A549) |
| Expression Pattern | down-regulated |
| Function Description | The knockdown of AK001796 by small interfering RNA reduced cellular cisplatin resistance and cell viability, and resulted in cell-cycle arrest, with a marked increase in the proportion of A549/DDP cells in the G0/G1 phase. By contrast, the knockdown of AK001796 increased the number of apoptotic cancer cells during cisplatin treatment. It was also shown that the knockdown of AK001796 positively induced the expression of cell apoptosis-associated factors, CCNC and BIRC5, and suppressed the expression of cell cycle-associated factors, CDK1 and GTSE5. Taken together, these fndings indicated that lncRNA AK001796 increased the resistance of NSCLC cells to cisplatin through regulating cell apoptosis and cell proliferation, and thus provides an attractive therapeutic target for NSCLC. |
| Pubmed ID | 29067469 |
| Year | 2017 |
| Title | Long non-coding RNA AK001796 contributes to cisplatin resistance of non-small cell lung cancer |
External Links
| Links for AK001796 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |